Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
PMID: 38399583
Source: Medicina (Kaunas)
Publication date:
2025-07-24
Year:
2024
Abstract
NULL